Correlate synaptic loss with cognition
- Trial ID
- NCT06875765
- Official Title
- Longitudinal Measurement of Synaptic Loss and Cognitive Decline in the Long-term Course of Parkinson's Disease
- Goal
- Correlate synaptic loss with cognition
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
- Study Type
- INTERVENTIONAL
- Enrollment
- 35 participants
- Conditions
- Parkinson Disease
- Interventions
- 11C-UCB-J PET-CT, 18F-PE2I PET-CT, MRI brain
Plain-Language Summary
The goal is to follow people with Parkinson's over time to see whether loss of synapses in the brain matches and helps predict long-term cognitive decline. Participants get PET scans with 11C-UCB-J, which binds the synaptic protein SV2A to measure synaptic density, and 18F-PE2I PET to measure dopamine transporter levels in nerve terminals, plus MRI for brain structure; these are observational imaging tests that do not change medications like levodopa, they only quantify brain changes. The study is looking for adults age 30 and up who are already in study S61477, who can have MRI, are not pregnant or breastfeeding, and do not have unrelated neuropsychiatric or major medical illnesses, recent significant radiation exposure, or a history of substance abuse.
Locations
- UZ Leuven, Leuven, Belgium
Frequently Asked Questions
- What is this trial testing?
- This trial is studying 11C-UCB-J PET-CT. The goal is to follow people with Parkinson's over time to see whether loss of synapses in the brain matches and helps predict long-term cognitive decline. Participants get PET scans with 11C-UCB-J, which binds the synaptic protein SV2A to measure synaptic density, and 18F-PE2I PET to measure dopamine transporter levels in nerve terminals, plus MRI for brain structure; these are observational imaging tests that do not change medications like levodopa, they only quantify brain changes. The study is looking for adults age 30 and up who are already in study S61477, who can have MRI, are not pregnant or breastfeeding, and do not have unrelated neuropsychiatric or major medical illnesses, recent significant radiation exposure, or a history of substance abuse.
- Who can participate?
- Participants must be at least 30 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 2 years and 5 months.